Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Peptides that act on melanocortin, oxytocin, and reproductive hormone pathways. The category includes one FDA-approved drug (bremelanotide / PT-141) and several research-stage compounds.
For a category as commercially intense as sexual wellness, the FDA-approved supply is shorter than the marketing copy suggests. Only one compound — bremelanotide, sold as Vyleesi — is FDA-approved with a sexual-desire indication, and only for a narrow patient population. Oxytocin has approvals in this category list but for obstetric indications, not for sexual wellness. Everything else either operates off-label, sits in active clinical research, or — in one notable case — lives in an illicit-market layer that the FDA and academic dermatologists have been documenting safety signals against for years. This page sorts out what's real, what's plausible, what's experimental, and what we'd be cautious about.
The only FDA-approved peptide for sexual wellness as of mid-2026 is bremelanotide (PT-141), marketed as Vyleesi. It was approved by FDA on June 21, 2019 under NDA 210557 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The original sponsor was Palatin Technologies, licensed at launch to AMAG Pharmaceuticals; commercial rights have since moved to Cosette Pharmaceuticals through a series of asset transactions. The drug is a subcutaneous injection delivered by autoinjector, used on-demand approximately 45 minutes before anticipated sexual activity, not as daily therapy.
Mechanistically, bremelanotide is a synthetic analog of α-melanocyte-stimulating hormone that activates multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R). The MC4R activation in the central nervous system is the proposed driver of the desire effect; the MC1R activation produces incidental skin pigmentation. The phase 3 RECONNECT trials — the basis for FDA approval — showed a modest but statistically significant improvement in measured sexual desire scores versus placebo in the HSDD population. The most common adverse events were nausea (about 40% of treated patients in the trials), flushing, injection-site reactions, and headache. The FDA approval is for premenopausal women only; an earlier development program for male hypoactive sexual desire was halted in the 2000s following blood-pressure signals at higher doses and has not been revived to FDA approval. Off-label use in men exists but does not have the indication or the controlled-trial dataset behind it.
The other FDA-approved peptide in this category is oxytocin, but its approval is for obstetric and gynecologic indications — Pitocin (NDA 018261) for induction and augmentation of labor, and the generic injectable (NDA 018248) for the same set of obstetric uses [12]. There is no FDA-approved oxytocin product for sexual wellness, bonding, or "intimacy" indications. Compounded intranasal oxytocin sold by some telehealth platforms operates outside the approved indications; we cover the regulatory architecture of compounded preparations in our compounded vs branded peptides explainer.
Among the research-stage compounds in this category, kisspeptin is the one with the deepest peer-reviewed evidence base and the cleanest mechanism story.
Kisspeptin is the peptide product of the KISS1 gene, discovered in the early 2000s as an upstream regulator of the hypothalamic-pituitary-gonadal axis. It stimulates GnRH neurons, driving downstream luteinizing hormone and follicle-stimulating hormone release. The relevance to sexual desire emerges from a separate observation: kisspeptin neurons project not only to the GnRH circuitry but also to limbic regions implicated in sexual processing.
The research program led by Professor Waljit Dhillo's group at Imperial College London has produced the most rigorous human trial data in the field. A 2022 randomized clinical trial published in JAMA Network Open reported that intravenous kisspeptin administration improved sexual brain processing on fMRI and self-reported sexual desire in women with HSDD [2]. A parallel 2023 trial in men with HSDD reported improvements in both fMRI sexual processing measures and penile tumescence in response to erotic stimuli [3]. Both trials are small (around 30-40 participants each), short-duration, and proof-of-concept by design — not pivotal phase 3 studies. A 2025 EBioMedicine paper described an intranasal kisspeptin formulation that rapidly stimulated gonadotropin release in humans, opening a more practical delivery route [4]. A separate program developing MVT-602, a kisspeptin receptor agonist, published phase 1 endocrine profiling in Fertility and Sterility in 2024 [5].
What this means in practice: kisspeptin is not commercially available outside clinical trial settings. There is no compounded or off-label kisspeptin product we would recommend purchasing. Telehealth platforms that advertise kisspeptin should be evaluated with skepticism, both for sourcing and for evidence base — the peer-reviewed data is promising but does not yet support a commercial indication.
Melanotan II is the compound in this category we would steer readers away from. It is not FDA-approved. The peer-reviewed safety signals over the past five to seven years are unusually concrete for a compound this widely available through illicit channels.
Mechanistically, Melanotan II is a synthetic α-MSH analog that activates multiple melanocortin receptor subtypes — including MC1R (producing the skin pigmentation that drives much of its illicit demand) and MC4R (producing the sexual-desire effect that drives the rest). It is structurally similar to bremelanotide / PT-141 but is not the same molecule — it has broader receptor activity and a longer half-life. Importantly, it was never developed through an FDA-track program; the academic team at the University of Arizona that synthesized it in the late 1980s did not pursue commercial development.
The documented safety signals:
- Renal infarction. A 2020 CEN Case Reports paper documented renal infarction in a user of Melanotan II and reviewed the prior case-report literature [6]. Cause and effect cannot be established from case reports, but the cluster is documented. - Priapism. A 2019 BMJ Case Reports paper documented priapism after Melanotan II self-administration [7] — consistent with the MC4R-mediated mechanism but a serious adverse event regardless. - Eruptive melanocytic nevi. A 2019 American Journal of Clinical Dermatology review covered the now well-documented pattern of new pigmented lesions appearing on the skin of Melanotan II users [8]. The clinical concern is that some of these lesions are dysplastic or atypical and require surveillance. - Oral mucosal melanoma. A 2025 International Journal of Oral and Maxillofacial Surgery paper specifically flagged Melanotan II nasal spray formulations as a possible risk factor for oral mucosal malignant melanoma [9]. This is the newest signal and it is alarming because nasal-spray Melanotan II products are increasingly sold online as a "needle-free" option. - Counterfeiting. A 2018 Journal of Pharmaceutical and Biomedical Analysis paper documented the broader problem of falsification of injectable peptide products including Melanotan-class compounds — sourcing through illicit channels means there is no quality guarantee on what the vial actually contains [10].
A patient considering Melanotan II for either pigmentation or libido has, in our editorial view, no good options. The FDA-approved alternative for sexual desire in premenopausal women is Vyleesi. There is no FDA-approved alternative for tanning that does not involve sun or UV exposure — Melanotan II is not the workaround.
Oxytocin is the most studied peptide in this category by volume of publications, and the most overhyped by marketing. The actual peer-reviewed signal for "intimacy," "bonding," or "social connection" indications is thin — and the strongest randomized trials of intranasal oxytocin in conditions where the bonding-hormone framing predicted benefit have generally been negative.
The 2021 NEJM trial of intranasal oxytocin in children and adolescents with autism spectrum disorder is the cleanest example [11]. The trial enrolled 290 participants over six months and reported no significant difference in social or behavioral outcomes between oxytocin and placebo. The trial was the most rigorous test of the "social neuropeptide" hypothesis in clinical practice and it did not support the hypothesis. A 2020 Pharmacological Reviews paper titled "Is Oxytocin 'Nature's Medicine'?" surveyed the broader pharmacology and was substantially more cautious than the popular framing [13].
The use cases where oxytocin has clear efficacy are obstetric and gynecologic: induction of labor (Pitocin), management of postpartum hemorrhage, and lactation support. These are the indications on the approved label. The use cases marketed for compounded intranasal or transdermal oxytocin — bonding, intimacy, mood support, sleep — do not have peer-reviewed RCT support equivalent to the obstetric indications.
That does not make compounded oxytocin necessarily unsafe at typical compounded doses, but it does mean a patient buying it should understand that the marketing claims are not on the approved label and are not supported by phase 3 trial data.
Vyleesi is available by prescription from licensed providers; the manufacturer (currently Cosette Pharmaceuticals) maintains a patient resource page with prescriber-locator information. Some telehealth platforms in our review set offer PT-141 — the most relevant for this category is TeleZenMD, which carries a PT-141 program. Where a telehealth platform offers "PT-141" as a compounded product rather than the branded Vyleesi, the questions to ask are the same as for any compounded peptide: which entity compounds the product, under which legal pathway (503A patient-specific compounding), and what the source pharmacy's quality history looks like. The compounding-architecture explainer covers the legal framework in detail.
For HSDD in postmenopausal women, Vyleesi is not on-label; flibanserin (Addyi) is the other FDA-approved HSDD drug and works through a different (serotonergic) mechanism. Neither drug is approved for men. Discussion with a clinician familiar with HSDD pharmacology is worth more than any provider-page comparison chart.
Vyleesi is the branded FDA-approved formulation of bremelanotide (also called PT-141). Compounded PT-141 sold by telehealth platforms uses the same active molecule but is not the FDA-approved drug — different manufacturing pathway, different quality oversight, no FDA-reviewed label. The chemistry can be identical when properly sourced; the regulatory standing is not.
No. The FDA approval (NDA 210557) is for HSDD in premenopausal women. A separate NDA seeking approval for men did not receive FDA approval. Off-label use in men exists but lacks the controlled-trial dataset.
The peer-reviewed case-report and review literature has documented renal infarction, priapism, eruptive melanocytic nevi, and a 2025 paper specifically raising oral mucosal melanoma concerns with nasal-spray formulations. Falsification of illicit Melanotan products is also documented. We do not recommend Melanotan II for any indication.
The strongest randomized evidence — including the 2021 NEJM trial in autism spectrum disorder — has been generally negative or null. The marketing framing of oxytocin as "nature's bonding hormone" outpaces the trial data substantially. Compounded oxytocin products for these indications are not on the FDA-approved label.
Not as of mid-2026. The compound has promising proof-of-concept randomized-trial data from the Imperial College London group [2][3] and ongoing development of a kisspeptin-receptor agonist (MVT-602) [5], but no FDA approval, no commercial drug, and no compounded preparation we would consider appropriately characterized. It remains an active research compound.
Editorial note: Informational only — not medical advice. Sexual wellness pharmacology, including HSDD treatment, should be discussed with a clinician familiar with the relevant literature. Last reviewed June 2026.